Array BioPharma Inc. – Nasdaq: ARRY
Shares of Array BioPharma Inc. are reaching levels unseen since 2007. Traded on the Nasdaq under ticker ARRY, the shares have reached over $10.00 on heavy volumes and are up over 160% in the last year. As late as 2016, shares were trading below $3.
Array BioPharma, based in Boulder, CO, is building a fully integrated, commercial-stage biopharmaceutical company that discovers, develops and markets safe and effective small molecule drugs to treat patients afflicted with cancer.
For 2016 Array BioPharma reported a loss of $0.65 EPS on revenues of $137 million. Nine firms follow Array and all nine rate ARRY as a “Strong Buy”.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
|Last Price a/o 2:09 PM EST||$ 10.00|
|Average Volume||3.83 million|
|Market Cap||$1.57 Billion|
|Shares Outstanding||166.29 million|
|Share Float||166.29 million|
|Short Interest Ratio||3.83|